Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 495 Results

Page 24 of 50« First «...10...22 232425 26...30 40 50...»Last »

April 4, 2019

DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

April 3, 2019

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

April 1, 2019

DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F

March 5, 2019

DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update

March 5, 2019

DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors

March 1, 2019

DBV Technologies to Attend Upcoming Investor Conferences

February 22, 2019

DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association

February 13, 2019

DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age

February 4, 2019

DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019

February 1, 2019

DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

Page 24 of 50« First «...10...22 232425 26...30 40 50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top